Efficacy and tolerability of calcitonin in the prevention and treatment of osteoporosis

BioDrugs

Volumn 10, Issue 4, 1998, Pages 295-300

  Halkin, Véronique ^a   Reginster, Jean Yves ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c Policliniques L BRULL Quai Godefroid Kurth   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; DRUG ANTIBODY; SALCATONIN;

ANALGESIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG DOSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; VERTEBRA FRACTURE;

EID: 0031770284     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810040-00004     Document Type: Article

References (42)

1. Wolffe HJ. Calcitonin; perspective in current concepts. J Endocrinol Invest 1982; 5: 523-30
2. MacIntyre I, Craig R. Molecular evolution of the calcitonins. In: Fink G, Whalley, J, editors. Neuropeptides: basic and clinical aspects. London: Churchill Livingstone, 1982: 255-8
3. Gaines Das RE, Zanelli JM. The international reference preparation of calcitonin, human, for bioassay: assessment of material and definition of the international unit. Acta Endocrinol 1980; 93: 37-42
4. Zimolo Z, Wesolowski G, Rodan AG. Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 1995; 96: 2277-83
5. Plosker GL, McTavish D. Intranasal salcatonin: a review of its pharmacological properties and in the management of postmenopausal osteoporosis. Drugs Aging 1996; 8: 378-400
6. Reginster JY. Ostéoporose postménopausique: traitement prophylactique. Paris: Masson, 1993; 127-37
7. Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24: 565-9
8. Ribot C, Tremollieres F, Pouilles JM, et al. Long-term effect of nasal calcitonin on vertebral and femoral bone mass in early menopause : results of a controlled prospective 3-year study. J Bone Miner Res 1992; 7 Suppl. 1: 196
9. Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus calcitonin given into different regimens in postmenopausal osteoporosis. Curr Ther Res 1985; 38: 455-64
10. Overgaard K, Hansen MA, Christiansen C. Effect of intranasal calcitonin on bone mass and bone turnover in early postmenopausal women: a dose-response study. J Bone Miner Res 1992; 7 Suppl. 1: 140
11. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 4 Suppl. 6: 629-632
12. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1991; 1: 7-14
13. McIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; I: 900-2
14. Geusens P, Boonen S, Nijs J. Effect of salmon calcitonin on femoral bone quality in adult ovariectomized ewes. Calcif Tissue Int 1996; 59: 315-20
15. Karachalios T, Lyritis GP, Giannarakos DG. Calcitonin effects on rabbit bone. Acta Orthop Scand 1992; 63: 615-8
16. Lyritis G, Magiasis B, Tsakalakos N. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 1995; 56: 38-41
17. Ellerington MC, Hillard TC, Whitecroft SIJ. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59: 6-11
18. Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452-8
19. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997; 36: 255-9
20. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993; 328: 1747-52
21. Kotaniemi A, Piirainen H, Paimela L, et al. Intranasal salmon calcitonin (sCT) prevents bone loss in active rheumatoid arthritis (RA) with low dose glucocorticoids [abstract]. Arthritis Rheum 1994; 37 Suppl. 9: 288
22. Canniggia A, Gennari C, Bencini M, et al. Calcium metabolism and 47-calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis. Clin Sci 1970; 38: 397-407
23. Milhaud G, Talbot JN, Coutris G. Calcitonin treatment of postmenopausal osteoporosis, evaluation of efficacy by principal component analysis. Biomedicine 1975; 23: 223-32
24. Reginster JY. Calcitonin for prevention and treatment of osteoporosis. Am J Med 1993; 95 Suppl. 1: 44-7
25. Rico H, Revilla M, Hernandez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56: 181-5
26. Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995; 17: 680-5
27. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35-9
28. Stock JL, Avioli LV, Baylink DJ. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three-year interim results of the PROOF study [abstract no. 187]. J Bone Miner Res 1997; 12 Suppl. 1: S149
29. Reginster JY, Gaspard S, Deroisy R. Prevention of osteoporosis with nasa salmon calcitonin: effect of anti-salmon calcitonin antibody formation. Osteoporos Int 1993; 3: 261-4
30. Takahashi S, Goldring S, Katz M, et al. Down-regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 1995; 95: 167-71
31. Reginster JY, Franchimont P. Side-effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985; 3: 155-7
32. Foti R, Martorana U, Broggini M. Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 1995; 56 Suppl. 4: 429-35
33. Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556-61
34. Thamsborg G, Storm TL, Sykulski R, et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991; 41: 302-7
35. Nagant De Deuxchaisnes C, Devogelaer JP, Huaux JP, et al. New modes of administration of salmon calcitonin in Paget's disease. Clin Orthop Relat Res 1987; 217: 56-71
36. Overgaard K, Aynusdei D, Hansen MA, et al. Dose-response bioactivity of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72: 344-9
37. Reginster JY, Denis D, Albert A, et al. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (im) or placebo injection in normal subjects. Bone Miner 1987; 2: 133-40
38. Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind study. Calcif Tissue Int 1986; 38: 3-8
39. Guidobono F, Netti C, Villani P, et al. Antinociceptive activity of eel calcitonin, injected into the inflamed paw in rats. Neuropharmacology 1991; 30: 1275-8
40. Ljunghall S, Gardsell P, Johnell O, et al. Synthetic human calcitonin in postmenopausal osteoporosis a placebo-controlled, double-blind study. Calcif Tissue Int 1991; 49: 17-9
41. Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double blind placebo-controlled clinical study. Calcif Tissue Int 1991; 49: 369-72
42. Pun KK, Shan LWL. Analgesic effect of salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989; 11: 205-9